NASDAQ:CYTX Cytori Therapeutics (CYTX) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free CYTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.60▼$1.7050-Day Range$0.20▼$0.2152-Week Range$0.20▼$0.75Volume16,331 shsAverage Volume915,302 shsMarket Capitalization$37.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Cytori Therapeutics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Cytori Therapeutics Stock (NASDAQ:CYTX)Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. CYTX Stock News HeadlinesFebruary 9, 2024 | investing.comCheckpoint Therapeutics Inc (CKPT)November 4, 2023 | morningstar.comSage Therapeutics Inc SAGEApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 27, 2023 | thestreet.com5 Biotech Stocks Under $10 Blasting HigherOctober 16, 2022 | finance.yahoo.comWomen’s Health Therapeutics Market Research Report by Type, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19August 29, 2022 | thestreet.com8 Stocks Under $10 Ripping HigherSee More Headlines Receive CYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryBiotechnology Current SymbolNASDAQ:CYTX CUSIP23283K10 CIK1095981 Webwww.cytori.com Phone858-458-0900FaxN/AEmployees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,630,000.00 Net Margins-242.60% Pretax MarginN/A Return on Equity-272.70% Return on Assets-56.23% Debt Debt-to-Equity Ratio0.39 Current Ratio0.46 Quick Ratio0.30 Sales & Book Value Annual Sales$3.67 million Price / Sales9.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book4.57Miscellaneous Outstanding Shares22,160,000Free FloatN/AMarket Cap$35.46 million OptionableNot Optionable Beta1.96 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMarc H. HedrickPresident, Chief Executive Officer & DirectorGary S. TitusChief Financial OfficerMark T. MarinoChief Medical Officer & Senior Vice PresidentJohn K. FraserChief ScientistRuss HavranekVP-Global Marketing & Business DevelopmentKey CompetitorsLENSARNASDAQ:LNSRCo-DiagnosticsNASDAQ:CODXLucid DiagnosticsNASDAQ:LUCDModular MedicalNASDAQ:MODDSpectral AINASDAQ:MDAIView All Competitors CYTX Stock Analysis - Frequently Asked Questions How were Cytori Therapeutics' earnings last quarter? Cytori Therapeutics Inc (NASDAQ:CYTX) released its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%. When did Cytori Therapeutics' stock split? Cytori Therapeutics's stock reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cytori Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX). This page (NASDAQ:CYTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.